Skip to main content

Table 2 Dosimetric results, as average ± SD over all patients

From: Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results

Structure

Parameter

All patients

Left side breast patients

Right side breast patients

Lung, ipsilateral

Mean [Gy]

7.6 ± 1.5

7.5 ± 1.2

7.7 ± 1.7

 

V20Gy [%]

7.6 ± 2.7

7.4 ± 2.0

7.7 ± 3.2

 

V5Gy [%]

50.9 ± 14.7

50.2 ± 13.3

51.7 ± 15.9

Lung, contralateral

Mean [Gy]

2.5 ± 1.3

2.4 ± 0.9

2.6 ± 1.6

Heart

Mean [Gy]

5.1 ± 2.1

6.0 ± 1.6

4.0 ± 2.1

 

V18Gy [%]

1.3 ± 1.7

2.3 ± 1.8

0.2 ± 0.4

 

V40Gy [%]

0.0 ± 0.0

0.0 ± 0.0

0.0 ± 0.0

Breast, contralateral

Mean [Gy]

2.3 ± 0.6

  

Skin

Mean [Gy]

22.7 ± 4.3

  

PTV_boost

St.Dev. [Gy]

0.9 ± 1.0

  

PTV_WB

St.Dev. [Gy]

1.5 ± 0.4

 Â